[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
March 18, 1939


Author Affiliations


From the Medical Department of the City of Detroit Receiving Hospital and Wayne University College of Medicine.

JAMA. 1939;112(11):1021-1027. doi:10.1001/jama.1939.02800110001001

Sulfanilamide has proved bacteriostatic against types I, II, III and XIV pneumococci in vitro and in laboratory animals, according to various authors.1 While the drug probably has been used widely for human pneumococcic pneumonia, the reports to date are meager. Heintzelman, Hadley and Mellon2 used it in nine cases of type III pneumonia and obtained seven recoveries, whereas among ten controls there were only two recoveries. Millett3 reported one case of type III pneumonia in which a crisis occurred after the use of sulfanilamide. Louis4 added six cases of pneumococcic pneumonia in which recovery occurred with sulfanilamide therapy.

The following report is based on 115 patients treated with sulfanilamide.5 compared with forty patients receiving serum and ninety-four controls receiving identical symptomatic and supportive measures but no specific therapy. While this series is too small to be statistically significant, it is reported in the hope that